Latest Market Access News

Streamplay Studio delivers a fourth consecutive quarter of positive cash flow, underpinned by steady publishing revenues and strategic platform growth in new regions.

Algorae Pharmaceuticals has struck an exclusive commercial and licensing agreement with global pharma Zydus Lifesciences to bring 10 injectable, oral, and specialty medicines to Australia and New Zealand, pending regulatory approvals.

Imricor Medical Systems advanced FDA clearances and expanded clinical trials in Q1 CY26, positioning for commercial growth despite higher operating cash outflows.

Vitrafy Life Sciences completed Phase II of its U.S. Military platelet cryopreservation study with strong results for a simplified no-wash process, accelerating commercial interest and progressing FDA device registration despite manufacturing delays.

American Tungsten & Antimony (ASX: AT4) has set up a Level 1 ADR program with Deutsche Bank, paving the way for its planned Nasdaq listing in Q2 2026 and opening U.S. dollar trading access for American investors.

EVE Health Group has appointed Ben Rohr as CEO, shifting Damian Wood to focus on regulatory and clinical affairs, aiming to sharpen commercial execution amid ongoing product rollouts.

TruScreen Group has met its FY2026 revenue guidance with a 41% jump in product sales, while investing heavily in new markets and pursuing a major UNITAID funding bid that could reshape its medium-term outlook.

Unico Silver has reported a 143% surge in its Joaquin project's mineral resource to 167 million ounces silver equivalent, reinforcing its status as a major silver developer. The company also progressed key pre-feasibility studies and expanded its investor reach with a US OTCQB listing.

EBR Systems secures Priority Review from Australia's TGA for its wireless cardiac pacing system, fast-tracking regulatory approval and expanding access for heart failure patients. This follows strong US commercial momentum after FDA approval.

Elixir Energy has completed its Lorelle-3/3H appraisal well with exceptional gas-condensate pay and the longest lateral drilled in the Taroom Trough. The company enters production testing phase fully funded with $22.3 million liquidity and a $10 million R&D-backed debt facility.

Tusker Minerals Ltd has seen its TSKO securities suspended from ASX quotation immediately due to non-compliance with listing rules. The suspension applies solely to this security class while the company works to meet regulatory requirements.

BCAL Diagnostics has expanded its Avantect cancer blood tests nationally through major pathology networks, generating $88,000 in Q3 revenue from 91 tests. The company also submitted an initial Medicare reimbursement application for pancreatic cancer detection and is preparing to launch an enhanced BREASTESTplus 2.0 test in early 2027.